Korean J Med > Volume 87(3); 2014 > Article
The Korean Journal of Medicine 2014;87(3):357-362.
Published online September 1, 2014.
DOI: https://doi.org/10.3904/kjm.2014.87.3.357   
A Case of Prolonged Hypogammaglobulinemia after Rituximab-Containing Chemotherapy in a Patient with Lymphoma
Hyun Jin Noh, Bong Han Gong, Young Sin Kim, Yun Hwa Jung, In Sook Woo, Chi Wha Han
Departments of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea
림프종 환자에서 리툭시맙 치료 후에 발생한 저감마글로불린혈증 1예
노현진, 공봉한, 김영신, 정윤화, 우인숙, 한치화
가톨릭대학교 의과대학 내과학교실
Correspondence: 
Chi Wha Han, Tel: +82-2-3779-2428, Fax: +82-2-780-3132, Email: cwhan@unitel.co.kr
Received: 25 February 2013   • Revised: 6 March 2013   • Accepted: 11 November 2013
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Rituximab, an anti-CD20 monoclonal antibody, is an effective target agent against the B lymphocytes in B-cell lymphoid malignancies and various lymphoproliferative diseases. Moreover, the toxicity of rituximab is less severe than that of conventional cytotoxic agents, which has promoted the widespread application of rituximab in the treatment of B-cell lymphoma. However, depletion of B lymphocytes by rituximab, which leads to secondary hypogammaglobulinemia, can cause deterioration of humoral immunity. Although immune reconstitution after hematopoietic stem cell transplantation is known to prevent prolonged hypogammaglobulinemia, very few cases of long-standing hypogammaglobulinemia have been reported. We report herein a case of prolonged hypogammaglobulinemia after rituximab-containing chemotherapy and splenectomy in a patient with non-Hodgkin’s lymphoma and discuss the clinical significance and pathogenetic mechanism of this phenomenon with a literature review.
Key Words: Non-Hodgkin’s lymphoma; Rituximab; IgG deficiency
주제어: 비호지킨림프종; 리툭시맙; 면역글로불린 G 결핍


TOOLS
METRICS Graph View
  • 1 Crossref
  •  0 Scopus
  • 2,787 View
  • 24 Download

Editorial Office
101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-2271-6791    Fax: +82-2-790-0993    E-mail: kaim@kams.or.kr                

Copyright © 2024 by The Korean Association of Internal Medicine.

Developed in M2PI

Close layer
prev next